10 Best Debt Free Mid Cap Stocks to Buy Now

6. Vaxcyte, Inc. (NASDAQ:PCVX)

Number of Hedge Fund Holders: 50

Enterprise Value: $7.43 billion

Market Capitalization: $9.11 billion

​Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company focused on developing high-fidelity vaccines to prevent or treat bacterial infectious diseases. The company’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease and is currently in Phase 2 clinical trials for infants. PCVX is also advancing VAX-31, a 31-valent PCV, which has completed a successful Phase 2 adult study and is expected to enter Phase 3 trials by mid-2025. Utilizing advanced chemistry and the XpressCF™ cell-free protein synthesis platform, the company aims to re-engineer vaccine production for enhanced immunological benefits. It is one of the best debt free stocks to invest in.

Vaxcyte, Inc. (NASDAQ:PCVX) demonstrated significant progress in 2024, particularly with its pneumococcal vaccine franchise, highlighted by stellar VAX-31 clinical data in adults announced in September. The company’s financial position remains robust, with $3.13 billion in cash, cash equivalents, and investments as of December 31, 2024, bolstered by $2.2 billion in net proceeds from two successful follow-on equity offerings. The VAX-31 Phase I/II study showed robust opsonophagocytic activity responses across all 31 serotypes, with the high dose demonstrating greater immune responses for 18 of 20 serotypes compared to PCV20. Based on these results, the FDA granted breakthrough therapy designation for VAX-31 in adults in November 2024.

Vaxcyte, Inc. (NASDAQ:PCVX) is advancing both VAX-24 and VAX-31 programs in infants, with VAX-24 infant Phase II study data expected by the end of Q1 2025 and VAX-31 infant program data anticipated by mid-2026. The company is also making significant progress in manufacturing scale-up through its partnership with Lonza, with a dedicated facility build-out on track for completion by early next year. The global pneumococcal vaccine market, currently valued at approximately $8 billion in annual sales, continues to expand with significant growth potential in the adult segment. Beyond the PCV franchise, PCVX is developing vaccines targeting other bacterial threats, including Group A Strep, Periodontitis, and Shigella, positioning itself at the forefront of addressing antimicrobial resistance.